Sign in
TerminatedNo phase

Specific Electrophenotypes in Atrial Fibrillation

Key facts

Who runs it
Imperial College London
Where
United Kingdom1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
1 person enrolled
Started
19 May 2022
Ended
27 Aug 2024
Type of study
Observational
Treatments tested
  • Biomarkers, electrocardiographic imaging, intracardiac electrograms, cardiac magnetic resonance imaging
Record updated
12 March 2026
Why it stopped
Study no longer has scientific value given findings from other studies

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Suitable candidate for catheter mapping/ablation for arrhythmias or direct current cardioversion for atrial fibrillation
  • Signed Informed Consent

Who cannot take part

  • Severe cerebrovascular disease
  • Active gastrointestinal bleeding
  • Active infection or fever
  • Severe uncontrolled systemic hypertension
  • Congestive heart failure - NYHA Class IV
  • Recent myocardial infarction
  • Bleeding or clotting disorders
  • Uncontrolled diabetes
  • Moderate to severe renal impairment (eGFR < 30)
  • Short life expectancy
  • Significant anaemia
  • Severe electrolyte imbalance
  • Inability to receive IV or oral Anticoagulants
  • Unable to give informed consent
  • Pregnancy

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study will investigate a common heart rhythm disturbance (arrhythmia), atrial fibrillation (AF), to improve understanding of how best to treat it in different patients. Direct current cardioversion (DCCV) is a procedure that can revert the heart to a normal rhythm, however almost all patients will only have a transient benefit, and their heart will return to the abnormal rhythm, AF. Ablation is an invasive procedure that creates scar tissue within the heart to reduce the arrhythmias, with a longer lasting effect than DCCV. It has been used with success in AF that occurs occasionally (paroxysmal) but is not as effective in AF that is more long-lasting, also known as persistent AF. Persistent AF is major cause of symptoms of breathlessness and palpitations and significantly increases the risk of stroke. Doctors are unable to accurately predict which patients will benefit most from an ablation, this can lead to as many as 50% of patients not benefitting from the procedure. The aim is to better predict which patients will benefit from an ablation. The study will include patients undergoing AF ablation or DCCV and perform additional tests including blood tests a heart MRI scan, a special type of heart tracing with up to 252 points and a short period of extra recordings from within the heart during the ablation procedure. Several techniques will be used to analyse this data, including machine learning, to develop a means predict which patients will benefit the most from the ablation procedure, without needing to use any recordings from within the heart.

Treatments tested

  • Biomarkers, electrocardiographic imaging, intracardiac electrograms, cardiac magnetic resonance imaging

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
IdeNtification of SPecific EleCTrophenotypes in Atrial Fibrillation
Record updated
12 March 2026